JP2018537501A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018537501A5 JP2018537501A5 JP2018531479A JP2018531479A JP2018537501A5 JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5 JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018531479 A JP2018531479 A JP 2018531479A JP 2018537501 A5 JP2018537501 A5 JP 2018537501A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- disease
- compound according
- ring
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 12
- 239000000203 mixture Substances 0.000 claims 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 4
- 125000005842 heteroatom Chemical group 0.000 claims 4
- 229910052757 nitrogen Inorganic materials 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 239000001301 oxygen Substances 0.000 claims 4
- 229910052717 sulfur Inorganic materials 0.000 claims 4
- 239000011593 sulfur Substances 0.000 claims 4
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 claims 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 claims 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 125000003118 aryl group Chemical group 0.000 claims 2
- 125000004429 atom Chemical group 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 2
- 208000025487 periodic fever syndrome Diseases 0.000 claims 2
- 229920006395 saturated elastomer Polymers 0.000 claims 2
- 208000007815 Acquired Hyperostosis Syndrome Diseases 0.000 claims 1
- 208000026326 Adult-onset Still disease Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000005024 Castleman disease Diseases 0.000 claims 1
- 206010008690 Chondrocalcinosis pyrophosphate Diseases 0.000 claims 1
- 208000015943 Coeliac disease Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 241001481833 Coryphaena hippurus Species 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 201000005569 Gout Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 claims 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 claims 1
- 208000003456 Juvenile Arthritis Diseases 0.000 claims 1
- 206010059176 Juvenile idiopathic arthritis Diseases 0.000 claims 1
- 208000005777 Lupus Nephritis Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 201000004854 SAPHO syndrome Diseases 0.000 claims 1
- 201000010848 Schnitzler Syndrome Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 201000009594 Systemic Scleroderma Diseases 0.000 claims 1
- 206010042953 Systemic sclerosis Diseases 0.000 claims 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000001931 aliphatic group Chemical group 0.000 claims 1
- 239000012472 biological sample Substances 0.000 claims 1
- 208000002849 chondrocalcinosis Diseases 0.000 claims 1
- 230000007812 deficiency Effects 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 201000002215 juvenile rheumatoid arthritis Diseases 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 201000008482 osteoarthritis Diseases 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021019843A JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A JP2023126574A (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562268765P | 2015-12-17 | 2015-12-17 | |
| US62/268,765 | 2015-12-17 | ||
| US201662353603P | 2016-06-23 | 2016-06-23 | |
| US62/353,603 | 2016-06-23 | ||
| PCT/US2016/067112 WO2017106607A1 (en) | 2015-12-17 | 2016-12-16 | Polycyclic tlr7/8 antagonists and use thereof in the treatment of immune disorders |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Division JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018537501A JP2018537501A (ja) | 2018-12-20 |
| JP2018537501A5 true JP2018537501A5 (enExample) | 2020-01-30 |
| JP6882299B2 JP6882299B2 (ja) | 2021-06-02 |
Family
ID=58191545
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018531479A Active JP6882299B2 (ja) | 2015-12-17 | 2016-12-16 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Pending JP2023126574A (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021019843A Active JP7317878B2 (ja) | 2015-12-17 | 2021-02-10 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
| JP2023117597A Pending JP2023126574A (ja) | 2015-12-17 | 2023-07-19 | 多環式ｔｌｒ７／８アンタゴニスト及び免疫障害の治療におけるそれらの使用 |
Country Status (29)
| Country | Link |
|---|---|
| US (7) | US10399957B2 (enExample) |
| EP (3) | EP3889146A1 (enExample) |
| JP (3) | JP6882299B2 (enExample) |
| KR (2) | KR20250043596A (enExample) |
| CN (2) | CN113603675A (enExample) |
| AU (3) | AU2016371014B2 (enExample) |
| CA (1) | CA3005766A1 (enExample) |
| CL (1) | CL2018001624A1 (enExample) |
| DK (1) | DK3889145T3 (enExample) |
| ES (2) | ES2981114T3 (enExample) |
| FI (1) | FI3889145T3 (enExample) |
| HR (1) | HRP20240355T1 (enExample) |
| HU (1) | HUE066591T2 (enExample) |
| IL (4) | IL259751B (enExample) |
| LT (1) | LT3889145T (enExample) |
| MX (2) | MX2021006804A (enExample) |
| MY (2) | MY196319A (enExample) |
| NZ (1) | NZ742476A (enExample) |
| PH (1) | PH12018501068A1 (enExample) |
| PL (1) | PL3889145T3 (enExample) |
| PT (1) | PT3889145T (enExample) |
| RS (1) | RS65319B1 (enExample) |
| SG (2) | SG11201804170RA (enExample) |
| SI (1) | SI3889145T1 (enExample) |
| SM (1) | SMT202400141T1 (enExample) |
| TW (3) | TWI886474B (enExample) |
| UA (1) | UA124802C2 (enExample) |
| WO (1) | WO2017106607A1 (enExample) |
| ZA (1) | ZA201803367B (enExample) |
Families Citing this family (108)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021006804A (es) * | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
| TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療 |
| RS63776B1 (sr) | 2016-07-14 | 2022-12-30 | Crinetics Pharmaceuticals Inc | Modulatori somatostatina i njihove upotrebe |
| RU2758686C2 (ru) * | 2016-08-08 | 2021-11-01 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
| MA46535A (fr) | 2016-10-14 | 2019-08-21 | Prec Biosciences Inc | Méganucléases modifiées spécifiques de séquences de reconnaissance dans le génome du virus de l'hépatite b |
| WO2018089695A1 (en) * | 2016-11-11 | 2018-05-17 | Dynavax Technologies Corporation | Toll-like receptor antagonist compounds and methods of use |
| CN110944990B (zh) | 2017-07-18 | 2024-06-18 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| CN117659025A (zh) * | 2017-10-30 | 2024-03-08 | 科罗拉多州立大学董事会法人团体 | Toll样受体8（tlr8）特异性拮抗剂及其制备方法和用途 |
| CA3086172A1 (en) * | 2017-12-19 | 2019-06-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| WO2019123339A1 (en) | 2017-12-20 | 2019-06-27 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
| AU2018392213B2 (en) | 2017-12-20 | 2021-03-04 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
| CN111699187A (zh) | 2018-02-12 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 用于治疗和预防病毒感染的新的砜化合物和衍生物 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| EP3774883A1 (en) | 2018-04-05 | 2021-02-17 | Gilead Sciences, Inc. | Antibodies and fragments thereof that bind hepatitis b virus protein x |
| TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
| TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | ２，２，─環二核苷酸 |
| TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
| TW201945388A (zh) | 2018-04-12 | 2019-12-01 | 美商精密生物科學公司 | 對b型肝炎病毒基因體中之識別序列具有特異性之最佳化之經工程化巨核酸酶 |
| TW202014193A (zh) | 2018-05-03 | 2020-04-16 | 捷克科學院有機化學與生物化學研究所 | 包含碳環核苷酸之2’3’－環二核苷酸 |
| WO2019233941A1 (en) * | 2018-06-05 | 2019-12-12 | F. Hoffmann-La Roche Ag | Tetrahydro-1 h-pyrazino[2,1 -ajisoindolylquinoline compounds for the treatment of autoimmune disease |
| US11713327B2 (en) | 2018-06-12 | 2023-08-01 | Hoffmann-La Roche Inc. | Heteroaryl heterocyclyl compounds for the treatment of autoimmune disease |
| CN112585134A (zh) * | 2018-06-13 | 2021-03-30 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的吡啶基杂环基化合物 |
| BR112020026681A2 (pt) | 2018-06-27 | 2021-04-06 | Bristol-Myers Squibb Company | Compostos naftiridinona substituídos úteis como ativadores de célula t |
| ES2950007T3 (es) | 2018-06-27 | 2023-10-04 | Bristol Myers Squibb Co | Compuestos de naftiridinona útiles como activadores de células T |
| EP3818052A1 (en) * | 2018-07-06 | 2021-05-12 | Gilead Sciences, Inc. | Therapeutic heterocyclic compounds |
| JPWO2020017569A1 (ja) * | 2018-07-17 | 2021-12-02 | 日本ケミファ株式会社 | Ｔ型カルシウムチャネル阻害剤 |
| JP7366994B2 (ja) * | 2018-07-23 | 2023-10-23 | エフ． ホフマン－ラ ロシュ アーゲー | 自己免疫疾患治療用の新規ピペラジン化合物 |
| MX2021000093A (es) * | 2018-07-31 | 2021-03-25 | Merck Patent Gmbh | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. |
| WO2020028097A1 (en) | 2018-08-01 | 2020-02-06 | Gilead Sciences, Inc. | Solid forms of (r)-11-(methoxymethyl)-12-(3-methoxypropoxy)-3,3-dimethyl-8-0x0-2,3,8,13b-tetrahydro-1h-pyrido[2,1-a]pyrrolo[1,2-c] phthalazine-7-c arboxylic acid |
| WO2020043271A1 (en) | 2018-08-28 | 2020-03-05 | F. Hoffmann-La Roche Ag | Novel pyrrolidinyl amide compounds for the treatment of autoimmune disease |
| US11639352B2 (en) | 2018-09-04 | 2023-05-02 | Hoffman-La Roche Inc. | Benzothiazole compounds for the treatment of autoimmune diseases |
| WO2020048595A1 (en) * | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel cyclic amidine compounds for the treatment of autoimmune disease |
| WO2020048596A1 (en) * | 2018-09-06 | 2020-03-12 | F. Hoffmann-La Roche Ag | Novel pyrazolopyridine compounds for the treatment of autoimmune disease |
| JP2022501326A (ja) * | 2018-09-07 | 2022-01-06 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 自己免疫疾患の治療のための新規ピロリジンアミン化合物 |
| CN112673007A (zh) * | 2018-09-11 | 2021-04-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的吡唑并吡啶胺化合物 |
| EP3623369B1 (en) | 2018-09-12 | 2023-10-25 | F. Hoffmann-La Roche AG | Novel morpholinyl amine compounds for the treatment of autoimmune disease |
| US20210395239A1 (en) * | 2018-09-27 | 2021-12-23 | Hoffmann-La Roche Inc. | Heterocyclyl compounds for the treatment of autoimmune disease |
| TWI721624B (zh) | 2018-10-31 | 2021-03-11 | 美商基利科學股份有限公司 | 經取代之6-氮雜苯并咪唑化合物 |
| CA3117556A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds as hpk1 inhibitors |
| CN109516925B (zh) * | 2018-10-31 | 2021-07-16 | 陕西慧康生物科技有限责任公司 | 一种谷氨酸-1-甲酯-5-叔丁酯的合成方法 |
| US20210300924A1 (en) * | 2018-11-09 | 2021-09-30 | Hoffmann-La Roche Inc. | 5-[6-[[3-(4,5,6,7-tetrahydropyrazolo[4,3-c]pyridin-1-yl)azetidin-1-yl]methyl]morpholin-4-yl]quinoline-8-carbonitrile derivatives and similar compounds as tlr7-9 antagonists for treating systemic lupus erythematosus |
| CN109369571A (zh) * | 2018-12-04 | 2019-02-22 | 无锡市赛乐新材料科技有限公司 | 一种含氟取代的7-溴-4-醛基苯并噻二唑及其合成方法 |
| US10689360B1 (en) | 2019-01-30 | 2020-06-23 | Insilico Medicine Ip Limited | TLR inhibitors |
| US11008303B2 (en) | 2019-01-30 | 2021-05-18 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| US11807622B2 (en) | 2019-01-30 | 2023-11-07 | Insilico Medicine Ip Limited | TLR 9 inhibitors |
| JP7637328B2 (ja) | 2019-02-07 | 2025-02-28 | ベイジーン リミテッド | Ｔｌｒ７アゴニストとしてのイミダゾ［２，１－ｆ］［１，２，４］トリアジン－４－アミン誘導体 |
| WO2020178770A1 (en) | 2019-03-07 | 2020-09-10 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
| JP7350871B2 (ja) | 2019-03-07 | 2023-09-26 | インスティチュート オブ オーガニック ケミストリー アンド バイオケミストリー エーエスシーアール，ヴイ．ヴイ．アイ． | ２’３’－環状ジヌクレオチドおよびそのプロドラッグ |
| EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
| JP2022081710A (ja) * | 2019-03-29 | 2022-06-01 | ユーティアイ リミテッド パートナーシップ | 関節リウマチを治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| WO2020203609A1 (ja) * | 2019-03-29 | 2020-10-08 | 日本ケミファ株式会社 | 掻痒を治療するためのｔ型カルシウムチャネル阻害剤の使用 |
| SG11202110401WA (en) * | 2019-04-09 | 2021-10-28 | Hoffmann La Roche | Hexahydro-1h-pyrazino[1,2-a]pyrazine compounds for the treatment of autoimmune disease |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| EP3972695A1 (en) | 2019-05-23 | 2022-03-30 | Gilead Sciences, Inc. | Substituted exo-methylene-oxindoles which are hpk1/map4k1 inhibitors |
| CN112094224B (zh) * | 2019-06-18 | 2022-08-26 | 浙江医药股份有限公司新昌制药厂 | 一种带保护基的3-取代-5-氨基哌啶的制备方法 |
| EP4017476A1 (en) | 2019-08-19 | 2022-06-29 | Gilead Sciences, Inc. | Pharmaceutical formulations of tenofovir alafenamide |
| CN112430208A (zh) * | 2019-08-26 | 2021-03-02 | 东莞市东阳光仿制药研发有限公司 | 一种pf-06651600中间体的制备方法 |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| EP4028125A1 (en) * | 2019-09-10 | 2022-07-20 | F. Hoffmann-La Roche AG | Novel quinoline compounds for the treatment of autoimmune disease |
| EP4031539A1 (en) | 2019-09-16 | 2022-07-27 | F. Hoffmann-La Roche AG | Piperidinyl amine compounds for the treatment of autoimmune disease |
| MY208114A (en) | 2019-09-30 | 2025-04-16 | Gilead Sciences Inc | Hbv vaccines and methods treating hbv |
| US11884647B2 (en) | 2019-10-18 | 2024-01-30 | The Regents Of The University Of California | Compounds and methods for targeting pathogenic blood vessels |
| WO2021084022A1 (en) * | 2019-10-31 | 2021-05-06 | F. Hoffmann-La Roche Ag | Hydropyrazino[1,2-d][1,4]diazepine compounds for the treatment of autoimmune disease |
| EP4058452B1 (en) * | 2019-11-12 | 2025-07-09 | F. Hoffmann-La Roche AG | Hydropyrazino[1,2-b]isoquinoline compounds for the treatment of autoimmune disease |
| CN114728976B (zh) * | 2019-11-19 | 2024-08-16 | 豪夫迈·罗氏有限公司 | 用于治疗自身免疫性疾病的氢-1H-吡咯并[1,2-a]吡嗪化合物 |
| WO2021099285A1 (en) * | 2019-11-19 | 2021-05-27 | F. Hoffmann-La Roche Ag | Triazatricycle compounds for the treatment of autoimmune disease |
| WO2021099406A1 (en) * | 2019-11-20 | 2021-05-27 | F. Hoffmann-La Roche Ag | Spiro(isobenzofuranazetidine) compounds for the treatment of autoimmune disease |
| PH12022551012A1 (en) * | 2019-11-26 | 2023-03-06 | Hoffmann La Roche | 1,8-naphthyridin-2-one compounds for the treatment of autoimmune disease |
| PH12022551260A1 (en) | 2019-11-28 | 2024-06-03 | Bayer Ag | Substituted aminoquinolones as dgkalpha inhibitors for immune activation |
| EP4069693B1 (en) | 2019-12-03 | 2024-03-20 | F. Hoffmann-La Roche AG | Hydropyrido[1,2-alpha]pyrazine compounds for the treatment of autoimmune diseases |
| CN116057068A (zh) | 2019-12-06 | 2023-05-02 | 精密生物科学公司 | 对乙型肝炎病毒基因组中的识别序列具有特异性的优化的工程化大范围核酸酶 |
| CN114846014B (zh) | 2019-12-18 | 2025-06-13 | 英特维特国际股份有限公司 | 包含氮杂吲哚结构的驱虫化合物 |
| BR112022012222A2 (pt) | 2019-12-23 | 2022-09-13 | Bristol Myers Squibb Co | Derivados de piperazina substituídos úteis como ativadores de células t |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| WO2021188959A1 (en) | 2020-03-20 | 2021-09-23 | Gilead Sciences, Inc. | Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same |
| CN116018139A (zh) * | 2020-05-14 | 2023-04-25 | 默克医疗保健股份两合公司 | 用于冠状病毒感染治疗的tlr7/8拮抗剂 |
| US20230301981A1 (en) * | 2020-06-15 | 2023-09-28 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| US20240350492A1 (en) | 2020-07-10 | 2024-10-24 | Ting Therapeutics Llc | Methods for the Prevention and Treatment of Hearing Loss |
| WO2022022489A1 (zh) * | 2020-07-27 | 2022-02-03 | 江苏恒瑞医药股份有限公司 | 吲哚稠环类衍生物、其制备方法及其在医药上的应用 |
| WO2022028389A1 (zh) * | 2020-08-03 | 2022-02-10 | 江苏恒瑞医药股份有限公司 | 稠三环类衍生物、其制备方法及其在医药上的应用 |
| CN114057754B (zh) * | 2020-08-07 | 2023-05-16 | 江苏恒瑞医药股份有限公司 | 含氮桥环类衍生物、其制备方法及其在医药上的应用 |
| CA3191084A1 (en) | 2020-09-09 | 2022-03-17 | Gerald Burke | Formulations of a somatostatin modulator |
| WO2022067462A1 (en) * | 2020-09-29 | 2022-04-07 | Beigene (Beijing) Co., Ltd. | Process for preparing inhibitors of kras g12c |
| KR102513463B1 (ko) * | 2020-11-26 | 2023-03-29 | 주식회사 에스앤케이테라퓨틱스 | 엔도솜 톨-유사 수용체를 제어하는 신규 소분자 화합물 및 이를 이용한 자가면역질환 치료제 |
| TW202227442A (zh) | 2020-11-26 | 2022-07-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 稠合三環化合物、其製備方法及其在醫藥上的應用 |
| CN115109032B (zh) * | 2021-03-18 | 2023-09-05 | 成都百裕制药股份有限公司 | 喹啉衍生物及其在医药上的应用 |
| AU2022257039A1 (en) | 2021-04-16 | 2023-10-05 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| TW202348237A (zh) | 2021-05-13 | 2023-12-16 | 美商基利科學股份有限公司 | TLR8調節化合物及抗HBV siRNA療法之組合 |
| JP7686091B2 (ja) | 2021-06-23 | 2025-05-30 | ギリアード サイエンシーズ， インコーポレイテッド | ジアシルグリセロールキナーゼ調節化合物 |
| CA3222277A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| EP4359389A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| AU2022298639C1 (en) | 2021-06-23 | 2025-07-17 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
| WO2023039464A1 (en) | 2021-09-10 | 2023-03-16 | Gilead Sciences, Inc. | Thienopyrrole compounds |
| CN115160296B (zh) * | 2022-08-08 | 2024-05-28 | 西安市第五医院 | 一种n-取代喹啉-4-胺类化合物及其制备、药物组合物和应用 |
| CN115650881B (zh) * | 2022-09-06 | 2025-01-17 | 浙江医药股份有限公司新昌制药厂 | 一种利用微反应器合成喹诺酮类化合物中间体的工艺方法 |
| WO2024153063A1 (zh) | 2023-01-18 | 2024-07-25 | 苏州科睿思制药有限公司 | Enpatoran的晶型及其制备方法和用途 |
| WO2025201636A1 (en) | 2023-03-31 | 2025-10-02 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025214612A1 (en) | 2023-04-14 | 2025-10-16 | Syngenta Crop Protection Ag | Pesticidally-active 2,2-dihalocyclopropyl compounds |
| WO2025032195A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form h1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hemihydrate |
| WO2025032197A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form of 5-((3r,5s)-3-amino-5-trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile |
| WO2025032190A1 (en) | 2023-08-09 | 2025-02-13 | Merck Patent Gmbh | Crystalline form a1 of 5-((3r,55)-3-amino-5- trifluoromethyl-piperidin-1-yl)-quinoline-8-carbonitrile hcl |
| WO2025160132A1 (en) * | 2024-01-23 | 2025-07-31 | Maplight Therapeutics, Inc. | Gpr6 inverse agonists |
| WO2025240242A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240246A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies with ribavirin |
| WO2025240244A1 (en) | 2024-05-13 | 2025-11-20 | Gilead Sciences, Inc. | Combination therapies comprising bulevirtide and lonafarnib for use in the treatment of hepatitis d virus infection |
| US20250345389A1 (en) | 2024-05-13 | 2025-11-13 | Gilead Sciences, Inc. | Combination therapies |
Family Cites Families (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US1020252A (en) * | 1911-04-26 | 1912-03-12 | Arthur H Bell | Brooder. |
| US1016829A (en) * | 1911-05-19 | 1912-02-06 | Abraham Hurwitz | Device for setting pallet-jewels. |
| US1227293A (en) * | 1914-04-10 | 1917-05-22 | Charles H Morison | Safety-catch for cuff-buttons. |
| US1271680A (en) * | 1918-01-15 | 1918-07-09 | Emanuel W Dunn | Heater. |
| US1367747A (en) * | 1919-05-07 | 1921-02-08 | George B Keplinger | Bath-brush |
| DE812911C (de) | 1945-03-12 | 1951-09-06 | Rhone Poulenc Sa | Verfahren zur Herstellung von neuen substituierten Derivaten des Piperidins |
| CH578535A5 (en) | 1973-05-11 | 1976-08-13 | Ciba Geigy Ag | Quinoline-3-carboxylic acid derivs - with e.g. analgesic, antinociceptive, antiinflammatory and antiallergic props |
| US4933447A (en) * | 1987-09-24 | 1990-06-12 | Ss Pharmaceutical Co., Ltd. | Quinoline derivatives |
| FR2798656B1 (fr) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| JP2005511625A (ja) | 2001-11-14 | 2005-04-28 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 向精神薬としてのピラゾール誘導体 |
| GB0206033D0 (en) | 2002-03-14 | 2002-04-24 | Pfizer Ltd | Compounds useful in therapy |
| WO2003105850A1 (en) | 2002-06-18 | 2003-12-24 | Abbott Laboratories | 2-aminoquinolines as melanin concentrating hormone receptor antagonists |
| WO2004016576A1 (ja) | 2002-08-12 | 2004-02-26 | Takeda Pharmaceutical Company Limited | 縮合ベンゼン誘導体および用途 |
| CA2505873A1 (en) | 2002-11-12 | 2004-05-27 | Pfizer Products Inc. | Quinoline derivatives |
| GB0227240D0 (en) | 2002-11-21 | 2002-12-31 | Glaxo Group Ltd | Compounds |
| GB0229281D0 (en) * | 2002-12-16 | 2003-01-22 | Novartis Ag | Organic compounds |
| US20050124625A1 (en) * | 2003-10-21 | 2005-06-09 | Salvati Mark E. | Piperazine derivatives and their use as modulators of nuclear hormone receptor function |
| JPWO2005087749A1 (ja) | 2004-03-15 | 2007-08-09 | 協和醗酵工業株式会社 | ２−アミノキナゾリン誘導体 |
| US20060211752A1 (en) | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| US20070004679A1 (en) | 2004-05-17 | 2007-01-04 | Nathalie Schlienger | Androgen receptor modulators and methods of treating disease using the same |
| AU2005247405A1 (en) | 2004-05-17 | 2005-12-08 | Acadia Pharmaceuticals Inc. | Androgen receptor modulators and method of treating disease using the same |
| JP2006056882A (ja) * | 2004-07-23 | 2006-03-02 | Tanabe Seiyaku Co Ltd | ピラゾロピリミジン化合物 |
| CN101023083A (zh) * | 2004-07-23 | 2007-08-22 | 田边制药株式会社 | 含氮的稠合双环化合物 |
| US20080081817A1 (en) | 2004-07-23 | 2008-04-03 | Tanabe Seiyaku Co., Ltd. | Nitrogenous Fused Bicyclic Compound |
| US20090264415A2 (en) | 2004-12-30 | 2009-10-22 | Steven De Jonghe | Pyrido(3,2-d)pyrimidines and pharmaceutical compositions useful for medical treatment |
| GB0510810D0 (en) | 2005-05-26 | 2005-06-29 | Novartis Ag | Organic compounds |
| GB0526042D0 (en) | 2005-12-21 | 2006-02-01 | Syngenta Participations Ag | Chemical compounds |
| WO2007097289A1 (ja) | 2006-02-20 | 2007-08-30 | Takeda Pharmaceutical Company Limited | 新規医薬 |
| HUE033894T2 (en) | 2006-08-23 | 2018-01-29 | Kudos Pharm Ltd | 2-Methylmorpholine pyrido-, pyrazo- and pyrimido-pyrimidine derivatives as MTOR inhibitors |
| EP1903038A1 (de) * | 2006-09-07 | 2008-03-26 | Bayer Schering Pharma Aktiengesellschaft | N-(1-Hetaryl-piperidin-4-yl)-(het)arylamide als EP2-Rezeptor Modulatoren |
| US20100004452A1 (en) | 2006-09-26 | 2010-01-07 | Barbara Bertani | 5-quinolinone derivatives as 5ht1a receptor modulators for treating sexual dysfunction, cognition impairment, psychotic disorders, anxiety, depression, etc. |
| CL2008001002A1 (es) | 2007-04-11 | 2008-10-17 | Actelion Pharmaceuticals Ltd | Compuestos derivados de oxazolidinona; composicion farmaceutica que comprende a dichos compuestos; y su uso para preparar un medicamento para tratar una infeccion bacteriana. |
| PT2164825E (pt) | 2007-06-05 | 2014-06-24 | Sanofi Sa | Derivados de di(hetero)arilciclo-hexano, sua preparação, sua utilização e composições farmacêuticas compreendendo os mesmos |
| CA2725416A1 (en) | 2008-05-12 | 2009-11-19 | Amnestix, Inc. | Compounds for improving learning and memory |
| JP2011526931A (ja) | 2008-07-03 | 2011-10-20 | エグゼリクシス， インコーポレイテッド | Ｃｄｋモジュレーター |
| US8735424B2 (en) * | 2008-09-02 | 2014-05-27 | Novartis Ag | Bicyclic kinase inhibitors |
| WO2010063352A1 (en) | 2008-12-01 | 2010-06-10 | Merck Patent Gmbh | 2, 5-diamino-substituted pyrido [4, 3-d] pyrimidines as autotaxin inhibitors against cancer |
| KR20110117705A (ko) | 2009-02-11 | 2011-10-27 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 톨-유사 수용체 조정제 및 질병의 치료 |
| EP2401275B1 (en) * | 2009-02-24 | 2013-07-24 | Respiratorius AB | Naphthyridine derivatives having bronchodilating activity |
| WO2011009015A1 (en) | 2009-07-16 | 2011-01-20 | Mallinckrodt Inc. | (+) - morphinans as antagonists of toll-like receptor 9 and therapeutic uses thereof |
| US20120214803A1 (en) * | 2011-02-18 | 2012-08-23 | Vifor (International) Ag | Novel Sulfonaminoquinoline Hepcidin Antagonists |
| WO2013060881A1 (en) | 2011-10-27 | 2013-05-02 | Vereniging Voor Christelijk Hoger Onderwijs, Wetenschappelijk Onderzoek En Patientenzorg | Pyridopyrimidines and their therapeutic use |
| WO2014086453A1 (en) | 2012-12-07 | 2014-06-12 | Merck Patent Gmbh | Azaheterobicyclic compounds |
| CA2916298C (en) | 2013-06-26 | 2021-10-12 | Abbvie Inc. | Primary carboxamides as btk inhibitors |
| TWI529171B (zh) * | 2013-07-29 | 2016-04-11 | 赫孚孟拉羅股份公司 | １，７－萘啶衍生物 |
| RU2718876C2 (ru) | 2013-08-23 | 2020-04-15 | Ньюфарма, Инк. | Некоторые химические соединения, композиции и способы |
| SG10201704327RA (en) * | 2013-10-14 | 2017-06-29 | Eisai R&D Man Co Ltd | Selectively substituted quinoline compounds |
| MX363708B (es) * | 2013-10-14 | 2019-03-29 | Eisai R&D Man Co Ltd | Compuestos de quinolina selectivamente sustituidos. |
| CN104557913B (zh) | 2013-10-28 | 2017-02-08 | 上海汇伦生命科技有限公司 | 吡啶并嘧啶类化合物，其制备方法和用途 |
| CA2933466A1 (en) * | 2013-12-13 | 2015-06-18 | Takeda Pharmaceutical Company Limited | Pyrrolo[3,2-c]pyridine derivatives as tlr inhibitors |
| WO2015092592A1 (en) | 2013-12-17 | 2015-06-25 | Pfizer Inc. | Novel 3,4-disubstituted-1h-pyrrolo[2,3-b]pyridines and 4,5-disubstituted-7h-pyrrolo[2,3-c]pyridazines as lrrk2 inhibitors |
| US9938282B2 (en) | 2014-02-05 | 2018-04-10 | Stereokem, Inc. | Expedient synthesis of sitagliptin |
| NZ724691A (en) | 2014-03-24 | 2018-02-23 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Quinoline derivatives as smo inhibitors |
| CN104945377A (zh) | 2014-03-24 | 2015-09-30 | 南京明德新药研发股份有限公司 | 作为smo抑制剂的喹啉衍生物 |
| AR100137A1 (es) | 2014-04-22 | 2016-09-14 | Hoffmann La Roche | Compuestos 4-amino-imidazoquinolina |
| GB201411236D0 (en) | 2014-06-25 | 2014-08-06 | Takeda Pharmaceutical | Novel compounds |
| US10590086B2 (en) | 2014-11-03 | 2020-03-17 | Iomet Pharma Ltd. | Pharmaceutical compound |
| UY36390A (es) | 2014-11-05 | 2016-06-01 | Flexus Biosciences Inc | Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen |
| WO2016087593A1 (en) | 2014-12-05 | 2016-06-09 | Syngenta Participations Ag | Novel fungicidal quinolinylamidines |
| MA41169A (fr) | 2014-12-17 | 2017-10-24 | Acraf | Composés antibactériens à large spectre d'activité |
| US10167270B2 (en) | 2015-07-01 | 2019-01-01 | Northwestern University | Substituted quinazoline compounds and uses thereof for modulating glucocerebrosidase activity |
| WO2017031427A1 (en) | 2015-08-19 | 2017-02-23 | 3-V Biosciences, Inc. | COMPOUNDS AND METHODS FOR INHIBITING mTOR |
| MX2021006804A (es) | 2015-12-17 | 2023-01-13 | Merck Patent Gmbh | Antagonistas policiclicos del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos en el tratamiento de trastornos inmunitarios. |
| RU2758686C2 (ru) | 2016-08-08 | 2021-11-01 | Мерк Патент Гмбх | Антагонисты tlr7/8 и их применение |
| CN110944990B (zh) | 2017-07-18 | 2024-06-18 | 默克专利股份公司 | Tlr7/8拮抗剂及其用途 |
| CA3086172A1 (en) | 2017-12-19 | 2019-06-27 | Merck Patent Gmbh | Tlr7/8 antagonists and uses thereof |
| MX2021000093A (es) * | 2018-07-31 | 2021-03-25 | Merck Patent Gmbh | Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos. |
-
2016
- 2016-12-16 MX MX2021006804A patent/MX2021006804A/es unknown
- 2016-12-16 ES ES21172996T patent/ES2981114T3/es active Active
- 2016-12-16 FI FIEP21172996.7T patent/FI3889145T3/fi active
- 2016-12-16 CA CA3005766A patent/CA3005766A1/en active Pending
- 2016-12-16 MY MYPI2018702111A patent/MY196319A/en unknown
- 2016-12-16 PT PT211729967T patent/PT3889145T/pt unknown
- 2016-12-16 KR KR1020257009400A patent/KR20250043596A/ko active Pending
- 2016-12-16 RS RS20240342A patent/RS65319B1/sr unknown
- 2016-12-16 MX MX2018006637A patent/MX385424B/es unknown
- 2016-12-16 CN CN202110952016.2A patent/CN113603675A/zh active Pending
- 2016-12-16 AU AU2016371014A patent/AU2016371014B2/en active Active
- 2016-12-16 WO PCT/US2016/067112 patent/WO2017106607A1/en not_active Ceased
- 2016-12-16 EP EP21172998.3A patent/EP3889146A1/en active Pending
- 2016-12-16 LT LTEP21172996.7T patent/LT3889145T/lt unknown
- 2016-12-16 HR HRP20240355TT patent/HRP20240355T1/hr unknown
- 2016-12-16 UA UAA201807881A patent/UA124802C2/uk unknown
- 2016-12-16 HU HUE21172996A patent/HUE066591T2/hu unknown
- 2016-12-16 SI SI201631813T patent/SI3889145T1/sl unknown
- 2016-12-16 MY MYPI2023001174A patent/MY210123A/en unknown
- 2016-12-16 CN CN201680081793.1A patent/CN108699032B/zh active Active
- 2016-12-16 SM SM20240141T patent/SMT202400141T1/it unknown
- 2016-12-16 PL PL21172996.7T patent/PL3889145T3/pl unknown
- 2016-12-16 ES ES16840344T patent/ES2883285T3/es active Active
- 2016-12-16 KR KR1020187018717A patent/KR102787063B1/ko active Active
- 2016-12-16 JP JP2018531479A patent/JP6882299B2/ja active Active
- 2016-12-16 EP EP16840344.2A patent/EP3390389B1/en active Active
- 2016-12-16 SG SG11201804170RA patent/SG11201804170RA/en unknown
- 2016-12-16 EP EP21172996.7A patent/EP3889145B1/en active Active
- 2016-12-16 SG SG10202001146PA patent/SG10202001146PA/en unknown
- 2016-12-16 DK DK21172996.7T patent/DK3889145T3/da active
- 2016-12-16 NZ NZ742476A patent/NZ742476A/en unknown
- 2016-12-16 US US15/381,406 patent/US10399957B2/en active Active
- 2016-12-19 TW TW112116054A patent/TWI886474B/zh active
- 2016-12-19 TW TW105142060A patent/TWI736566B/zh active
- 2016-12-19 TW TW110137731A patent/TWI804003B/zh active
-
2018
- 2018-05-17 PH PH12018501068A patent/PH12018501068A1/en unknown
- 2018-05-21 ZA ZA2018/03367A patent/ZA201803367B/en unknown
- 2018-05-31 IL IL259751A patent/IL259751B/en active IP Right Grant
- 2018-05-31 IL IL279751A patent/IL279751B/en active IP Right Grant
- 2018-06-15 CL CL2018001624A patent/CL2018001624A1/es unknown
-
2019
- 2019-07-10 US US16/507,870 patent/US10544122B2/en active Active
- 2019-11-26 US US16/696,503 patent/US10696649B2/en active Active
-
2020
- 2020-04-28 US US15/929,348 patent/US10947213B1/en active Active
- 2020-12-19 US US17/128,021 patent/US11629134B2/en active Active
- 2020-12-24 IL IL279752A patent/IL279752B2/en unknown
- 2020-12-24 IL IL279751A patent/IL279751A/en active IP Right Grant
-
2021
- 2021-02-10 JP JP2021019843A patent/JP7317878B2/ja active Active
- 2021-08-17 AU AU2021218041A patent/AU2021218041B2/en active Active
-
2023
- 2023-03-06 US US18/179,211 patent/US20230303514A1/en not_active Abandoned
- 2023-07-19 JP JP2023117597A patent/JP2023126574A/ja active Pending
- 2023-12-18 AU AU2023285714A patent/AU2023285714A1/en not_active Abandoned
-
2024
- 2024-10-23 US US18/923,917 patent/US20250059157A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018537501A5 (enExample) | ||
| JP2019527718A5 (enExample) | ||
| JP2020537671A5 (enExample) | ||
| HRP20200179T1 (hr) | Spojevi heteroarila kao inhibitori irak i njihova uporaba | |
| RU2019105719A (ru) | Антагонисты tlr7/8 и их применение | |
| HRP20240355T1 (hr) | 8-cijano-5-piperidino-kinolini kao tlr7/8 antagonisti i njihova upotreba u liječenju imunoloških poremećaja | |
| TWI776994B (zh) | 經碸吡啶烷基醯胺取代之雜芳基化合物 | |
| RU2020123151A (ru) | Антагонисты tlr7/8 и их применение | |
| JP2017524733A5 (enExample) | ||
| JP2017530959A5 (enExample) | ||
| FI3788044T3 (fi) | RIP1:tä estäviä yhdisteitä ja menetelmiä niiden valmistamiseksi ja käyttämiseksi | |
| RU2020115596A (ru) | ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ TBK/IKKε И ИХ ПРИМЕНЕНИЯ | |
| JP2017538689A5 (enExample) | ||
| JP2017509586A5 (enExample) | ||
| JP2018536634A5 (enExample) | ||
| RU2019131017A (ru) | Соединения гетероарила в качестве ингибиторов btk и их применение | |
| JP2014533281A5 (enExample) | ||
| JP2020517611A5 (enExample) | ||
| JP2018538248A5 (enExample) | ||
| RU2018102685A (ru) | СОЕДИНЕНИЯ-ИНГИБИТОРЫ TBK/IKKε И ИХ ПРИМЕНЕНИЕ | |
| JP2017502092A5 (enExample) | ||
| JP2016529315A5 (enExample) | ||
| RU2017105133A (ru) | Индолизиновые производные, которые применяют при нейродегенеративных заболеваниях | |
| JP2017520538A5 (enExample) | ||
| JP2015507004A5 (enExample) |